Jump to main content
Jump to site search


Co-delivery of DNAzyme and a chemotherapy drug using a DNA tetrahedron for enhanced anticancer therapy through synergistic effects

Author affiliations

Abstract

A DNA tetrahedron, which could be rapidly and reliably assembled by annealing four customized ssDNA oligonucleotides, has been regarded as one of the most promising nanocarriers. However, engineering of a DNA tetrahedron allowing co-delivery of two or more drugs for synergistic therapy has been largely unexplored. Herein, we report a nanocarrier composed of a DNA tetrahedron (Td), a ZY11-targeting aptamer, anticancer drug doxorubicin (Dox), and 17E DNAzyme to achieve synergistic chemo-gene cancer therapy. First, the nanocarrier was assembled by annealing. Dox can be loaded onto the DNA tetrahedron through intercalation and released in a pH-dependent manner. The obtained Dox@Aptamer–Td–DNAzyme (Dox@Ap–Td–Dz) not only demonstrated an excellent efficiency of gene suppression but also exhibited a good pH-responsive drug release behavior. Hence, the presented DNA tetrahedron based multifunctional nanoplatform can achieve a targeted and synergistic chemo-gene therapy, which provides great potential in improving the curative efficiency.

Graphical abstract: Co-delivery of DNAzyme and a chemotherapy drug using a DNA tetrahedron for enhanced anticancer therapy through synergistic effects

Back to tab navigation

Supplementary files

Publication details

The article was received on 31 May 2019, accepted on 01 Aug 2019 and first published on 02 Aug 2019


Article type: Paper
DOI: 10.1039/C9NJ02818H
New J. Chem., 2019, Advance Article

  •   Request permissions

    Co-delivery of DNAzyme and a chemotherapy drug using a DNA tetrahedron for enhanced anticancer therapy through synergistic effects

    T. Ren, Z. Deng, H. Liu, X. Li, J. Li, J. Yuan, Y. He, Q. Liu, Y. Yang and S. Zhong, New J. Chem., 2019, Advance Article , DOI: 10.1039/C9NJ02818H

Search articles by author

Spotlight

Advertisements